Morten Hjelmsoe offers a quick review of the development of our communication technologies- and looks forward to what’s coming next.
Morten Hjelmsoe offers a quick review of the development of our communication technologies- and looks forward to what’s coming next.
We started out taking our paper materials – our detail aids and brochures – and digitizing them. This meant that we could transport things easier but also enabled a bit of interactivity – charts would move, animations could play.
Morten Hjelmsoe
This was OK, but not really very smart. So the next step was to add some intelligence – a CRM backend to the system.
This enabled us to do some limited tracking. It was limited because it only measured message delivery – you could see what was said but learned nothing about what was actually received. And to get even this limited data, our sales force had to keep heading back to base and plugging in their devices (laptops in the early days).
To solve that, the systems went ‘into the cloud’. This kept the reps on the road. But the systems still weren’t very user friendly or appropriate to the life sciences business. So then we get a ‘pharma layer’ added to these systems.
This was fine, but basically was still CRM, so it could still only really track what we said and not what our customers thought of it. And that brings us to today.
The arrival of real CLM means that we can finally start to understand what our customers thought about our communications.
It’s interesting to me that, as we went through this technology development process, something really important emerged. Have a read back and you’ll see what there was a fundamental shift in focus from us to our customers. So rather than build a system around what suits us, we can now shape our communications around our customers.
It’s a revolution. The very best CLM technology places the customer at the center of a web of multichannel communications that that they drive. This switch from ‘push’ to ‘pull’ really is revolutionary because it means that we’re working on an individual level.
So – following a little bit of discovery – we can understand what each customer needs to know and how we can help him or her. It not only takes the guesswork out of marketing but also removes antagonism from our customer outreach.
So that’s where we are today – quietly going about a pretty fundamental revolution.
So what then about tomorrow?
The next step – and one that we can take very soon – is to empower the same process between the doctor and the patient. The industry’s shift ‘beyond the pill’ necessarily draws us further into the treatment process: creating new demands and responsibilities. But it’s not about replacing medical professionals. The very CLM technology that placed doctors in the centre of our communication can keep them there when they interact with their patients.
So for the future, we just need to expand our understanding of what the technology can do. Exciting times ahead!
Morten Hjelmsoe is the CEO and founder of Agnitio.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.